Indeed, enhanced GRK5 activity has been associated with favorable, β-blocker treatment-like outcomes in human CHF [32] with attenuated atherosclerosis [33] and with better cardiac function in humans/CHF patients [34]. This evidence concerns the gene GRK5 and congestive heart failure.